API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the agreement, Menarini will develop, manufacture and commercialise orally administered Janus kinase (JAK) inhibitor Smyraf Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis.
Lead Product(s): Peficitinib Hydrobromide
Therapeutic Area: Immunology Product Name: Smyraf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 12, 2023